|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 冷水机利用变流量冷冻水的若干设计问题显示文摘目前变水量冷冻水系统的设计一般都采用一、二次双环路方式。但这种双环路配置方式会产生:使用两个水泵增加设备投资;冷冻水送水及回水的混合影响冷水机在部分负荷时的效率;实际的高负荷空调需求条件与最大设计工况条件不吻合时不能充分利用冷水机的全负荷容量等不良后果。设计单环路空调冷冻水系统可以避免上述问题。讨论了单环路变流量系统的长处以及可能产生的问题,并提供在整个运行范围内,能够实现安全、稳定和可靠的冷水机控制策略。 | Original by Thomas B. Hartman Translation by Liu Xuemin Reviewed by Steve Y. Chen | 1997 | 暖通空调1997，27，3： | 18 |
| 2 | All -variable speed centrifugal chiller plants: can we make our plants more efficient 显示文摘 | Thomas Hartman | 2002 | Automated Buildings2002，，3： | 1 |
| 3 | All - variable speed chilled water distribution systems : optimizing distribution eflleieney 显示文摘 | Thomas Hartman | 2002 | Automated Buildings2002，，4： | 1 |
| 4 | Idiopathic Pulmonary Fibrosis: Evolving Concepts显示文摘 | Jay H. Ryu Teng Moua Craig E. Daniels Thomas E. Hartman Eunhee S. Yi James P. Utz Andrew H. Limper | 2014 | Mayo Clinic Proceedings2014，，： | 1 |
| 5 | Diffuse Bronchiolar Disease Due to Chronic Occult Aspiration显示文摘 | Terrance W. Barnes Robert Vassallo Henry D. Tazelaar Thomas E. Hartman Jay H. Ryu | 2006 | Mayo Clinic Proceedings2006，，2： | 1 |
| 6 | All-variable speed centrifugal chiller plants显示文摘 | Thomas B Hartman | 2001 | ASHRAE Journal2001，，1： | 1 |
| 7 | Diagnesis of thoracic complication in AII SI Accuracy of CT显示文摘 | Thomas E Hartman SL Primack NL | 1994 | AJR1994，162，： | 1 |
| 8 | All-variable speed centrifugal chiller plants显示文摘 | Thomas Hartman | 2001 | ASHRAE Journal2001，43，9： | 1 |
| 9 | Ultra-efficient cooling with demandbased control显示文摘 | Thomas Hartman | 2001 | HPAC Engineering2001，，12： | 1 |
| 10 | Designing efficient systems with the equal marginal performance principle显示文摘 | Thomas Hartman | 2005 | ASHRAE Journal2005，47，7： | 1 |
| 11 | Chiller-plant control using gateway technologies显示文摘 | Thomas Hartman | 2000 | HPAC Engineering2000，，1： | 1 |
| 12 | Relational control显示文摘 | Thomas Hartman | 2005 | HPAC Engineering2005，，10： | 1 |
| 13 | Biodegradation of [S,S], [R,R] and mixed stereoisomers of Ethylene Diamine Disuccinic Acid (EDDS), a transition metal chelator显示文摘 | Diederik Schowanek Tom C.J. Feijtel Christopher M. Perkins Frederick A. Hartman Thomas W. Federle Robert J. Larson | 1997 | Chemosphere1997，，11： | 1 |
| 14 | Presenting intelligent iterative control:PID replacement for setpoint control(part1)显示文摘 | Thomas Hartman | 2003 | HPAC Engineering2003，，9： | 1 |
| 15 | Diagnosis of thoracic complications in AlDS:Accuracy of CT显示文摘 | Thomas E Hartman Steven L Primack Nestor L Muller | 1994 | AJR1994，162，3： | 1 |
| 16 | Presenting intelligent iterative control:PID replacement for setpoint control(pard)显示文摘 | Thomas Hartman | 2003 | HPAC Engineering2003，，10： | 1 |
| 17 | Design issues of variable chilledwater flow through chillers 显示文摘 | Hartman Thomas B | 1996 | ASHRAE Transactions1996，，102： | 1 |
| 18 | Presenting intelligent iterative control:PID replacement for setpoint control(part3)显示文摘 | Thomas Hartman | 2003 | HPAC Engineering2003，，11： | 1 |
| 19 | PID control:may it rest in peacetechnology in obsolete in the age of digital networks显示文摘 | Thomas Hartman | 2002 | HPAC Engineering2002，，7： | 1 |
| 20 | Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results显示文摘AIM To assess the real-world effectiveness and cost of simeprevir(SMV), and/or sofosbuvir(SOF)-based therapy for chronic hepatitis C virus(HCV) infection.METHODS The real-world performance of patients treated with SMV/SOF ± ribavirin(RBV), SOF/RBV, and SOF/RBV with pegylated-interferon(PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included. Rates of sustained virological response-the absence of a detectable serum HCV RNA 12 wk after the end of treatment [sustained virological response(SVR) 12]-were calculated on an intention-to-treat basis. Costs were calculated from the payer's perspective using Medicare/Medicaid fees and Redbook Wholesale Acquisition Costs. Patient-related factors associated with SVR12 were identified using multivariable logistic regression.RESULTS SVR 12 rates were as follows: 86%(95%CI: 80%-91%)among 178 patients on SMV/SOF ± RBV; 62%(95%CI: 55%-68%) among 234 patients on SOF/RBV; and 78%(95%CI: 68%-86%) among 96 patients on SOF/PEG/RBV. Mean costs-per-SVR 12 were $174442(standard deviation: ± $18588) for SMV/SOF ± RBV; $223003(± $77946) for SOF/RBV; and $126496(± $31052) for SOF/PEG/RBV. Among patients on SMV/SOF ± RBV, SVR12 was less likely in patients previously treated with a protease inhibitor [odds ratio(OR): 0.20, 95%CI: 0.06-0.56]. Higher bilirubin(OR: 0.47, 95%CI: 0.30-0.69) reduced the likelihood of SVR12 among patients on SOF/RBV, while FIB-4 score ≥ 3.25 reduced the likelihood of SVR 12(OR: 0.18, 95%CI: 0.05-0.59) among those on SOF/PEG/RBV. CONCLUSION SVR 12 rates for SMV and/or SOF-based regimens in a diverse real-world population are comparable to those in clinical trials. Treatment failure accounts for 27% of costs. | Kian Bichoupan Neeta Tandon James F Crismale Joshua Hartman David Del Bello Neal Patel Sweta Chekuri Alyson Harty Michel Ng Keith M Sigel Meena B Bansal Priya Grewal Charissa Y Chang Jennifer Leong Gene Y Im Lawrence U Liu Joseph A Odin Nancy Bach Scott L Friedman Thomas D Schiano Ponni V Perumalswami Douglas T Dieterich Andrea D Branch | 2017 | World Journal of Virology2017，6，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员